Aurexo Therapeutics – Reimagining Medicine Through the Power of Exosome

Company Overview

Aurexo Therapeutics in collaboration with Henry Ford Health is a preclinical stage company developing engineered Lactobacillus-derived extracellular vesicles (E-BEVs) as a novel biologics platform for targeted oncology. Our company's current lead program is focused on Triple-Negative Breast Cancer, with preclinical in-vivo and in-vivo data supporting selective tumor targeting and further development toward IND-enabling studies.

Our Mission

Our mission is to develop breakthrough cancer biologics by utilizing E-BEVs that will precisely target diseased cells, spare healthy tissues, and deliver meaningful clinical impact for patients who need safer, more effective treatment options.

Our Vision

Our vision is to establish Aurexo Therapeutics as a global leader in novel engineered therapeutics - advancing a new class of biologics that redifines how cancer and complex diseases are treated while addressing clinical unmet patient needs.

About Us

Welcome to Aurexo Therapeutics

"Aurexo Therapeutics is pioneering a novel class of non-toxic oncology therapeutics, built upon our proprietary engineered bacterial extracellular vesicle (e-BEV) platform. In collaboration with Henry Ford Health, we have successfully validated our lead therapeutic candidate, AeBEV-001, through rigorous in vitro and in vivo preclinical models, demonstrating an 80% targeted cytotoxicity rate against Triple-Negative Breast Cancer (TNBC) tumors with zero systemic toxicity to normal, healthy cells. Backed by this robust proof-of-concept data, we are actively advancing AeBEV-001 through PK/PD profiling and IND-enabling safety studies. Furthermore, the modular nature of our platform has allowed us to rapidly initiate R&D programs for colon (AeBEV-002) and pancreatic (AeBEV-003) cancers."

Corporate Development & Partnering Opportunities

To accelerate the translation of our e-BEV platform into human clinical trials, Aurexo Therapeutics is actively seeking strategic investment and biopharmaceutical alliances. We offer attractive engagement pathways for qualified partners, including: Co-Development & Financing: Strategic investment rounds to fund IND-enabling toxicology, stability, and Phase 1 clinical readiness. Pharma Alliances & Licensing: Global or regional licensing opportunities for our lead asset, AeBEV-001, as well as collaborative discovery partnerships utilizing our proprietary e-BEV delivery platform.

Beyond Chemo, Bovine Exosomes and Liposomes
Our E-BEVs Standalone Efficacy & Zero Toxicity

Rethinking Targeted Delivery
Established delivery platforms deployed across major pharma—including Roche, Eli Lilly, Takeda, etc—continue to face key technical hurdles. Technologies relying on liposomes, LNPs, or Mammalian Stem Cell exosomes, BOVINE exosomes, and Plant-derived exosomes often require harsh chemical conjugations and toxic therapeutic payloads (such as cytotoxic small molecules or siRNAs) to drive efficacy. Our platform bypasses these hurdles.

By engineering extracellular vesicles with precise cell-binding specificity and natural effector function, we deliver robust therapeutic impact while minimizing systemic toxicity and simplifying downstream manufacturing.

Aurexo’s E-BEVs are naturally derived and bio-programmed,
which acts directly as a therapeutic agent to destroy cancer.

Validated Efficacy: Completed in vitro and in vivo preclinical validation, showcasing an 80% tumor cell destruction rate in TNBC models.
Pristine Safety Profile: Demonstrated absolute cellular precision by selectively killing malignant cells with zero harm to normal tissue lines.
Clear Regulatory Pathway: Actively progressing through PK/PD profiling to fulfill IND-enabling requirements for AeBEV-001.
Scalable Pipeline: R&D expansion underway for colon (AeBEV-002) and pancreatic (AeBEV-003).
Strategic Opportunity: Open to institutional investment and biopharmaceutical licensing alliances to drive clinical translation.

Chemotherapy Drugs and Small Molecules

Highly Toxic, Off Target and Rapid Clearance

Bovine, Stem Cells and Plant Exosomes

Requires Chemotherapy Drugs, Small molecules or siRNA

Liposomes and LNPs Therapy

Synthetic, Toxic and Requires Chemotherapy Drugs, Small molecules or siRNA

Car T-Cell and ADC Therapy

Personalized, Targeted but Very Expensive

Novel E-BEVs Therapy

Aurexo's E-BEV are Derived from Engineered Gut Friendly Lactobacillus Bacteria, without using Drug or Small Molecules, which is Highly Safe for Cancer Therapy

Our Innovations

The Problem and Our Solution: Precision Bioengineering

Traditional oncology treatments are limited by systemic toxicity—chemotherapies destroy healthy tissue alongside malignant cells. Aurexo Therapeutics breaks this trade-off by introducing a novel class of targeted oncology therapeutics that eliminate tumors while leaving normal, healthy cells entirely unaffected.

Engineered Probiotic
Extracellular Vesicles (e-BEVs)

Our proprietary approach harnesses Engineered Lactobacillus Extracellular Vesicles (e-BEVs)—an advanced exosome-based platform exclusively licensed from

HENRY FORD HEALTH.

Derived from beneficial probiotic bacteria, these bio-engineered vehicles are reprogrammed to serve as highly precise, non-toxic cancer-killing agents.

Dual-Action Mechanism of Action
(MoA)

Our e-BEV platform operates via a powerful, multi-pronged therapeutic pathway:

Absolute Tumor Selectivity

Our e-BEVs naturally recognize, bind to, and destroy malignant cells while completely sparing normal tissue lines.

Metastasis Inhibition

Beyond primary tumor reduction, preclinical data confirms our e-BEVs dynamically halt cellular migration, stopping the spread of cancer to secondary organs.

Immune System Activation

The platform triggers a localized immune response, significantly increasing critical cytokine production to recruit the host immune system to fight the tumor.

Absolute Tumor Selectivity

E-BEV induces selective cell death across multiple cancer types. E-BEV selectively eliminates diverse human cancer cell lines, including TNBC (right). Broad efficacy is also observed in lung cancer lines (left) regardless of oncogenic mutations (KRAS, EGFR, ALK).

Unlocking a Safer Path to a Cure

By replacing toxic chemotherapies with bio-programmed, probiotic-derived vesicles, Aurexo is building a future where cancer treatment is both ruthlessly effective against tumors and entirely safe for the patient.

Our initial clinical focus is targeted towards developing a life-saving drug for Triple-Negative Breast Cancer (TNBC) – a highly aggressive cancer with a critical lack of targeted options – before expanding our platform to address pancreatic, colon, lung, and prostate cancers.

Figure showing experimental timeline of TNBC tumor growth in nude mice. Triple-negative breast cancer (TNBC) cells were implanted into nude mice. E-BEVs was administered orally at week 3, and tumor growth was monitored for six weeks. The result shows almost 80% tumor regression when treated with E-BEVs.

Pipeline

Our Solution: Precision Bioengineering

Traditional oncology treatments are often limited by systemic toxicity—chemotherapies destroy healthy tissue alongside malignant cells. Aurexo Therapeutics breaks this trade-off by introducing a novel class of targeted oncology therapeutics that eliminate tumors while leaving normal, healthy cells entirely unaffected.

Engineered Probiotic Extracellular Vesicles (e-BEVs)

Our proprietary approach harnesses Engineered Lactobacillus Extracellular Vesicles (e-BEVs)—an advanced exosome-based platform exclusively licensed from Henry Ford Health. Derived from beneficial probiotic bacteria, these bio-engineered vehicles are reprogrammed to serve as highly precise, non-toxic cancer-killing agents.

Dual-Action Mechanism of Action (MoA)

Our e-BEV platform operates via a powerful, multi-pronged therapeutic pathway:

• Absolute Tumor Selectivity: Our e-BEVs naturally recognize, bind to, and destroy malignant cells while completely sparing normal tissue lines.

• Metastasis Inhibition: Beyond primary tumor reduction, preclinical data confirms our e-BEVs dynamically halt cellular migration, stopping the spread of cancer to secondary organs.

• Immune System Activation: The platform triggers a localized immune response, significantly increasing critical cytokine production to recruit the host immune system to fight the tumor.

Unlocking a Safer Path to a Cure

Lead Program: AeBEV-001 (Triple-Negative Breast Cancer)

Aurexo Therapeutics has successfully completed robust in vitro and in vivo preclinical validation for our lead therapeutic candidate, AeBEV-001. The platform has demonstrated remarkable, highly selective cytotoxicity, achieving an 80% targeted destruction rate of triple-negative breast cancer (TNBC) cells in preclinical models while leaving normal, healthy tissue lines completely unaffected.

Based on these definitive safety and efficacy profiles, AeBEV-001 is actively progressing through pharmacokinetics (PK) and pharmacodynamics (PD) profiling to complete its IND-enabling data package.

Platform Expansion: AeBEV-002 & AeBEV-003

Leveraging the powerful foundational data established by our engineered bacterial extracellular vesicle (e-BEV) platform, Aurexo has initiated discovery and R&D programs targeting two additional high-impact oncology indications:

AeBEV-002: Colon Cancer (Discovery/R&D Phase)
AeBEV-003: Pancreatic Cancer (Discovery/R&D Phase)

Corporate Development & Partnering Opportunities

Co-Development & Financing: Strategic investment rounds to fund IND-enabling toxicology, stability, and Phase 1 clinical readiness.
Pharma Alliances & Licensing: Global or regional licensing opportunities for our lead asset, AeBEV-001, as well as collaborative discovery partnerships utilizing our proprietary e-BEV delivery platform.

Security Enhanced

We always provide people a complete solution focused of any business.

Cloud Computing

We always provide people a complete solution focused of any business.

Cryptocurrency

We always provide people a complete solution focused of any business.

Let's Start

Start Your Business with brainstorming

Business

Consulting

Strategy

Get Started

Testimonials

Customers Reviews

Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway.

Monty Moni

CEO, Keen IT Solution

Mike Hotten

CEO, Brick Consulting

John Bhai

CEO, Brick Consulting

Jorina Bibi

CEO, Brick Consulting

Delu Beta

CEO, Brick Consulting

Our Leadership

Meet the experts behind Aurexo Therapeutics. Our diverse team combines scientific excellence,
innovation, and industry experience to develop groundbreaking eBEV-based therapies for the future of oncology.